|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
3
|
Das B, Sarkar N, Bishayee A and Sinha D:
Dietary phytochemicals in the regulation of epithelial to
mesenchymal transition and associated enzymes: A promising
anticancer therapeutic approach. Semin Cancer Biol. 56:196–218.
2019. View Article : Google Scholar
|
|
4
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
|
|
5
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Annu
Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boesch M, Spizzo G and Seeber A: Concise
review: Aggressive colorectal cancer: Role of epithelial cell
adhesion molecule in cancer stem cells and
epithelial-to-mesenchymal transition. Stem Cells Transl Med.
7:495–501. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hardie DG and Sakamoto K: AMPK: A key
sensor of fuel and energy status in skeletal muscle. Physiology
(Bethesda). 21:48–60. 2006.
|
|
9
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lizcano JM, Göransson O, Toth R, Deak M,
Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG and
Alessi DR: LKB1 is a master kinase that activates 13 kinases of the
AMPK subfamily, including MARK/PAR-1. EMBO J. 23:833–843. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ji S, Tang S, Li K, Li Z, Liang W, Qiao X,
Wang Q, Yu S and Ye M: Licoricidin inhibits the growth of SW480
human colorectal adenocarcinoma cells in vitro and in vivo by
inducing cycle arrest, apoptosis and autophagy. Toxicol Appl
Pharmacol. 326:25–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thent ZC, Zaidun NH, Azmi MF, Senin MI,
Haslan H and Salehuddin R: Is metformin a therapeutic paradigm for
colorectal cancer: Insight into the molecular pathway? . Curr Drug
Targets. 18:734–750. 2017. View Article : Google Scholar
|
|
14
|
Clements J, Hooper J, Dong Y and Harvey T:
The expanded human kallikrein (KLK) gene family: Genomic
organisation, tissue-specific expression and potential functions.
Biol Chem. 382:5–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Di Meo A, Wang C, Cheng Y, Diamandis EP
and Yousef GM: The miRNA-kallikrein interaction: A mosaic of
epigenetic regulation in cancer. Biol Chem. 399:973–982. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Talieri M, Li L, Zheng Y, Alexopoulou DK,
Soosaipillai A, Scorilas A, Xynopoulos D and Diamandis EP: The use
of kallikrein-related peptidases as adjuvant prognostic markers in
colorectal cancer. Br J Cancer. 100:1659–1665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lawrence MG, Lai J and Clements JA:
Kallikreins on steroids: Structure, function, and hormonal
regulation of prostate-specific antigen and the extended kallikrein
locus. Endocr Rev. 31:407–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Lu Z, Cui M, Yang Q, Tang Y and
Dong Q: Tissue kallikrein protects SH-SY5Y neuronal cells against
oxygen and glucose deprivation-induced injury through bradykinin B2
receptor-dependent regulation of autophagy induction. J Neurochem.
139:208–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Talieri M, Devetzi M, Scorilas A, Pappa E,
Tsapralis N, Missitzis I and Ardavanis A: Human kallikrein-related
peptidase 12 (KLK12) splice variants expression in breast cancer
and their clinical impact. Tumour Biol. 33:1075–1084. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwon Y, Park M, Jang M, Yun S, Kim WK, Kim
S, Paik S, Lee HJ, Hong S, Kim TI, et al: Prognosis of stage III
colorectal carcinomas with FOLFOX adjuvant chemotherapy can be
predicted by molecular subtype. Oncotarget. 8:39367–39381. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Geng X, Liu Y, Dreyer T, Bronger H,
Drecoll E, Magdolen V and Dorn J: Elevated tumor tissue protein
expression levels of kallikrein-related peptidases KLK10 and KLK11
are associated with a better prognosis in advanced high-grade
serous ovarian cancer patients. Am J Cancer Res. 8:1856–1864.
2018.PubMed/NCBI
|
|
23
|
Tailor PD, Kodeboyina SK, Bai S, Patel N,
Sharma S, Ratnani A, Copland JA, She JX and Sharma A: Diagnostic
and prognostic biomarker potential of kallikrein family genes in
different cancer types. Oncotarget. 9:17876–17888. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li XS and He XL: Kallikrein 12
downregulation reduces AGS gastric cancer cell proliferation and
migration. Genet Mol Res. 15:2016.
|
|
25
|
Lose F, Batra J, O'Mara T, Fahey P,
Marquart L, Eeles RA, Easton DF, Al Olama AA, Kote-Jarai Z, Guy M,
et al: Common variation in Kallikrein genes KLK5, KLK6, KLK12, and
KLK13 and risk of prostate cancer and tumor aggressiveness. Urol
Oncol. 31:635–643. 2013. View Article : Google Scholar
|
|
26
|
Zhao EH, Shen ZY, Liu H, Jin X and Cao H:
Clinical significance of human kallikrein 12 gene expression in
gastric cancer. World. J Gastroenterol. 18:6597–6604. 2012.
|
|
27
|
Kryza T, Parent C, Pardessus J, Petit A,
Burlaud-Gaillard J, Reverdiau P, Iochmann S, Labas V, Courty Y and
Heuzé-Vourc'h N: Human kallikrein-related peptidase 12 stimulates
endothelial cell migration by remodeling the fibronectin matrix.
Sci Rep. 8:63312018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang R, Li J, Yan X, Jin K, Li W, Liu X,
Zhao J, Shang W and Zhao X: Long noncoding RNA MLK7AS-1 promotes
proliferation in human colorectal cancer via downregulation of p21
expression. Mol Med Rep. 19:1210–1221. 2019.
|
|
29
|
Wang Y, Hong D, Qian Y, Tu X, Wang K, Yang
X, Shao S, Kong X, Lou Z and Jin L: Lupeol inhibits growth and
migration in two human colorectal cancer cell lines by suppression
of Wnt-β-catenin pathway. Onco Targets Ther. 11:7987–7999. 2018.
View Article : Google Scholar :
|
|
30
|
Cork GK, Thompson J and Slawson C: Real
Talk: The inter-play between the mTOR, AMPK, and hexosamine
biosynthetic pathways in cell signaling. Front Endocrinol
(Lausanne). 9:pp. 5222018, View Article : Google Scholar
|
|
31
|
Lyu SC, Han DD, Li XL, Ma J, Wu Q, Dong
HM, Bai C and He Q: Fyn knockdown inhibits migration and invasion
in cholangiocarcinoma through the activated AMPK/mTOR signaling
pathway. Oncol Lett. 15:2085–2090. 2018.PubMed/NCBI
|
|
32
|
Papachristopoulou G, Tsapralis N,
Michaelidou K, Ardavanis-Loukeris G, Griniatsos I, Scorilas A and
Talieri M: Human kallikrein-related peptidase 12 (KLK12) splice
variants discriminate benign from cancerous breast tumors. Clin
Biochem. 58:78–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jia S, Qu T, Wang X, Feng M, Yang Y, Feng
X, Ma R, Li W, Hu Y, Feng Y, et al: KIAA-1199 promotes migration
and invasion by Wnt/β-catenin pathway and MMPs mediated EMT
progression and serves as a poor prognosis marker in gastric
cancer. PLoS One. 12:pp. e01750582017, View Article : Google Scholar
|
|
34
|
Yang D, Du G, Xu A, Xi X and Li D:
Expression of miR-149-3pinhibits proliferation, migration, and
invasion of bladder cancer by targeting S100A4. Am J Cancer Res.
7:2209–2219. 2017.
|
